The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Advancing host-directed therapy for tuberculosis
Abstract
Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, repeated higher doses of drugs are needed to reach therapeutic levels, which is one of the major reasons for MDR-TB.201”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [201]
Citations
Cites
Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response
Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schauber, J., Wu, K., Meinken, C., et al. (2006) · Science · doi:10.1126/science.1123933 · Cited by 3,924
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S. K., Wise, R. P., Mirabile‐Levens, E., Kasznica, J. M., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,683
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Gutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004) · Cell · doi:10.1016/j.cell.2004.11.038 · Cited by 2,252
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,198
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,171
Research works printed but not linked: 2
- Trafford, G. et al. Anti-TNF therapy for severe CNS tuberculosis causing blindness. Eur. Conf. Clin. Micro. Infect. Dis. [online] , (2013).
- Winthrop, K. L. et al. Tuberculosis and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. Abstr. 64 (Suppl. 10), 1278 (2012).
Cited by
Sorted by citations
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. F. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 869
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.69 · Cited by 502
A major role for ferroptosis in Mycobacterium tuberculosis –induced cell death and tissue necrosis
Amaral, E. P., Costa, D. L., Namasivayam, S., Riteau, N., Kamenyeva, O., Mittereder, L., Mayer-Barber, K. D., Andrade, B. B., & Sher, A. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181776 · Cited by 464
Dynamic balance of pro‐ and anti‐inflammatory signals controls disease and limits pathology
Cicchese, J. M., Evans, S., Hult, C., Joslyn, L. R., Wessler, T., Millar, J. A., Marino, S., Cilfone, N. A., Mattila, J. T., Linderman, J. J., et al. (2018) · Immunological Reviews · doi:10.1111/imr.12671 · Cited by 344
Metadata
- Authors
- Wallis, R. S., & Hafner, R.
- Affiliations
- Aurum Institute (ZA)
- National Institutes of Health (US)
- Corresponding author
- Wallis, Robert S.
- Venue
- Nature Reviews Immunology
- Published
- 2015-03-13
- Volume
- 15
- Issue
- 4
- Pages
- 255-263
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1980411188
- Cited by
- 291
- References
- 121
- Citations by year
- 2026: 20 · 2025: 13 · 2024: 14 · 2023: 16 · 2022: 19 · 2021: 26 · 2020: 34 · 2019: 39 · 2018: 33 · 2017: 35 · 2016: 28 · 2015: 14
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (HHSN272201200009C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis, host-directed therapy, Mycobacterium tuberculosis, adjunctive therapy, autophagy, antimicrobial peptides, lung injury, treatment duration, antimicrobial resistance, lung inflammation
- MeSH terms
- Humans, Immunity, Inflammation, Mycobacterium tuberculosis, Tuberculosis, Host-Pathogen Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
